Literature DB >> 31421144

Assessing the Impact of Time to Cystectomy for Variant Histology of Urothelial Bladder Cancer.

Michael Lin-Brande1, Shane M Pearce1, Akbar N Ashrafi1, Azadeh Nazemi1, Madeleine L Burg1, Saum Ghodoussipour1, Gus Miranda1, Hooman Djaladat1, Anne Schuckman1, Siamak Daneshmand2.   

Abstract

OBJECTIVE: To determine if the timing of radical cystectomy for variant histology of urothelial carcinoma has an impact on survival. Variant histology has been associated with aberrant behavior compared to pure urothelial carcinoma, however the timing of surgery for these patients has not been studied.
MATERIALS AND METHODS: We identified 363 patients with cT2-T4N0M0 urothelial carcinoma who underwent radical cystectomy without perioperative intravesical and/or systemic therapy from 2003 to 2014. Clinicopathologic data were compared between pure urothelial carcinoma and variant histology. The time from diagnosis to radical cystectomy was analyzed as a continuous variable and dichotomized at 4-, 8-, and 12-weeks to determine impact on oncologic outcomes.
RESULTS: Patients with variant histology, when compared to those with pure urothelial carcinoma, were more likely to present with extravesical disease (P <.01), be upstaged (P <.01), have lymphovascular invasion (P <.01) and have lymph node metastasis at radical cystectomy (P = .02). The median days to radical cystectomy did not differ between pure urothelial and variant histology. On multivariable analysis controlling for age, comorbidities, tumor stage, lymph node status, lymphovascular invasion, and surgical margins, every month in delay was associated with a worse overall survival for variants (HR = 1.36, P = .003). At an 8-week delay or longer, those with variant histology had a statistically worse survival (P = .03).
CONCLUSION: For patients with variant histology, delays in surgery were associated with an increased risk of death.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31421144     DOI: 10.1016/j.urology.2019.07.034

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  MicroRNAs Which Can Prognosticate Aggressiveness of Bladder Cancer.

Authors:  Edyta Marta Borkowska; Tomasz Konecki; Michał Pietrusiński; Maciej Borowiec; Zbigniew Jabłonowski
Journal:  Cancers (Basel)       Date:  2019-10-14       Impact factor: 6.639

Review 2.  A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond.

Authors:  Jeffrey J Leow; Wei Shen Tan; Wei Phin Tan; Teck Wei Tan; Vinson Wai-Shun Chan; Kari A O Tikkinen; Ashish Kamat; Shomik Sengupta; Maxwell V Meng; Shahrokh Shariat; Morgan Roupret; Karel Decaestecker; Nikhil Vasdev; Yew Lam Chong; Dmitry Enikeev; Gianluca Giannarini; Vincenzo Ficarra; Jeremy Yuen-Chun Teoh
Journal:  Front Surg       Date:  2022-10-04

Review 3.  Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic.

Authors:  Christopher J D Wallis; Giacomo Novara; Laura Marandino; Axel Bex; Ashish M Kamat; R Jeffrey Karnes; Todd M Morgan; Nicolas Mottet; Silke Gillessen; Alberto Bossi; Morgan Roupret; Thomas Powles; Andrea Necchi; James W F Catto; Zachary Klaassen
Journal:  Eur Urol       Date:  2020-05-03       Impact factor: 20.096

Review 4.  Bladder Cancer at the time of COVID-19 Outbreak.

Authors:  Francesco Esperto; Karl H Pang; Simone Albisinni; Rocco Papalia; Roberto M Scarpa
Journal:  Int Braz J Urol       Date:  2020-07       Impact factor: 1.541

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.